NCT07428538

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-01-29Est. Completion: 2027-11

Enrollment target: 350 participants

Locations

University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
University of South Alabama, Mobile, Alabama, United States
Banner - University Medical Center, Phoenix, Arizona, Phoenix, Arizona, United States
Mayo Clinic - Phoenix, Phoenix, Arizona, United States
Southern California GI & Liver Centers - Coronado, Coronado, California, United States
Scripps, La Jolla, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
UCLA Health - Ronald Reagan Medical Center, Los Angeles, California, United States
Stanford Medicine - Clinical and Translational Research Unit - Redwood City, Redwood City, California, United States
University of California at Davis Medical Center, Sacramento, California, United States
Sutter Health, San Francisco, California, United States
Yale School of Medicine, New Haven, Connecticut, United States
Georgetown University Medical Center, Washington D.C., District of Columbia, United States
Mayo Clinic, Jacksonville, Florida, United States
Reliant Medical Research, Miami, Florida, United States

Chronic Hepatitis B Infection

France is a low-endemicity country for hepatitis B virus (HBV) infection. In 2016, the prevalence of chronic HBV infecti…

Créteil, FranceEst. completion Sep 1, 2029

Hepatitis E

Hepatitis E is well known to be a common cause of severe hepatitis on organ-transplanted people. However, several studie…

Les Abymes, GuadeloupeCompleted May 5, 2019

Drug Induced Liver InjuryPruritus

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.